S ystemic scleroderma (SSc) is a multisystem disease with microvascular abnormalities, autoimmune disorders, excessive collagen production and deposition, fi brosis of skin and internal organs, with progressive course and potentially fatal outcome (1, 2, 3, 4) .
Due to a wide variety of clinical manifestations, common resemblance or co-occurrence with other connective tissue diseases, attempts to develop an adequate classifi cation have been made for years. In 1962, Tuff anelli and Winkelmann proposed three forms of scleroderma based on skin involvement and severity: 1. acrosclerosis, 2. diff use scleroderma, and 3. acute diff use scleroderma (5) . In 1978, based on his experience, Barnett suggested three subsets: 1. sclerodactyly; 2. sclerosis limited to the forearms, without trunk classifi cation of SSc (10) , diff erentiating acral systemic scleroderma, or sclerodactyly and proximal systemic scleroderma; the single major criterion is scleroderma proximal to the digits, aff ecting the limbs, face, neck or trunk; or at least two minor criteria such as sclerodactyly or digital pitted scarring or bilateral basal pulmonary fi brosis. In 1996, the Committee of the American Academy of Dermatology proposed a comprehensive classifi cation of cutaneous sclerosis in three large groups: A. primary cutaneous sclerosis, which includes diff use systemic or limited systemic (CREST syndrome), localized or circumscribed without involvement of internal organs, part of the overlap syndrome (mixed and poorly diff erentiated connective tissue disease) and eosinophilic faciitis; B. secondary cutaneous sclerosis as a result of GVHD (graft versus host disease), use of medications, intoxication, infection; C. prodromal cutaneous sclerosis syndromes, primarily Raynaud's phenomenon (11). Apart from diff use and limited systemic cutaneous sclerosis, in 2001, LeRoy and Medsger described also ectopic calcinosis and telangiectasias and limited unclassifi ed prescleroderma, the so-called pre-systemic scleroderma (12) . Th ey introduced new criteria, including nailfold capillary microscopic abnormalities and the presence of autoantibodies, in order to establish patients with early limited systemic sclerosis without skin involvement. It is also called SS without skin involvement, visceral sclerosis, or SS sine scleroderma (13, 14) .
In 2004, Maricq and Walter selected the following criteria for the classifi cation of systemic sclerosis (SS): 1. sclerodermatous skin involvement; 2. microvascular abnormalities specifi c to SSc: SDtype nailfold capillary changes and/or CREST-type capillary telangiectasia; 3. presence of anticentromere antibodies (ACA) (14) . Based on these criteria they proposed the following classifi cation:
I Diff use sclerosis (all three criteria) II Intermediate sclerosis (2 criteria) III Digital sclerosis (one criterion) IV Sclerosis without skin involvement (none of the criteria) V Insuffi ciently diff erentiated connective tissue disease with sclerosis (one or none of the criteria) VI CREST (one or none of the criteria).
Serbian Journal of Dermatology and Venereology 2015; 7 (3): [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] In 2007, Walker et al. adapted the LeRoy and Medsger classifi cation which included the following types: limited systemic scleroderma, limited systemic scleroderma with cutaneous involvement, diff use systemic scleroderma and diff use fasciitis with eosinophilia (15) .
Scleroderma spectrum disorders involve the existence of the following (16): 1. diff use systemic sclerosis; 2. limited cutaneous systemic sclerosis with CREST syndrome as a variation;
3. systemic sclerosis sine scleroderma; 4. localized scleroderma with linear scleroderma; 5. mixed connective tissue disease with features of systemic sclerosis, polymyositis, and SLE.
6. overlap syndromes: systemic sclerosis plus polymyositis, rheumatoid arthritis, or SLE.
7. scleroderma mimics -amyloidosis, chronic graftversus-host disease, diff use fasciitis with eosinophilia, eosinophilia-myalgia syndrome, nephrogenic fi brosing dermopathy, paraneoplastic syndromes, scleredema, scleromyxedema (papular mucinosis), toxic oil syndrome;
8. undiff erentiated connective tissue disease: multiple nonspecifi c, serologic or clinical abnormalities that do not meet ACR (American College of Rheumatology) criteria for rheumatic disease.
We report a patient with limited systemic scleroderma -CREST syndrome.
Case Report
A female patient, 66 years of age, fi rst noticed skin changes at the age of 43. Th ey progressed during the following 10 -15 years, but after that time, they mostly persisted unchanged, with occasional bacterial and fungal secondary infections. Th e disease lasted for 23 years, and resulted in fatal outcome at the age of 66. In the last eleven years, she was hospitalized several times.
Th e fi rst symptoms appeared on the acral areas of hands which were cold, turning white, purple then red. At fi rst, the attacks were cold induced, later they became more frequent, regardless of the temperature, involving the toes as well. In the following two years, these were the only symptoms of the disease, but later the fi ngers got pale, hard, with impaired mobility, subsequently leading to inability to fully stretch them, which signifi cantly aff ected activities of daily living. Th e nails became thin and fragile. Th e skin of the distal portions of the arms and legs became thinner and tight. Th e involvement of the face started fi ve years after the appearance of fi rst symptoms; facial skin also became tight, thin and hard, without wrinkles. Th e face became smaller, wrinkles were prominent around the mouth, whereas dry mouth caused diffi culties when smiling, laughing, talking or chewing food. Th en, fi rm yellowish nodules developed on the fi nger joints, as well as large solid nodules on the shoulders and thighs. At that time, the patient started experiencing diffi culties swallowing, heartburn, and regurgitation after large meals. No other organ involvement was reported.
Th e patient reported no serious illnesses. Th ere was no family history of a similar condition.
Physical examination
Upon skin examination, the skin was pale, yellowish in color, thight, smooth, taut, and mask like. Th e face got smaller, with radial furrows around the mouth, causing the skin to stretch so that the few residual teeth were visible due to gingival retraction. Th e beaked nose and deep-sunken eyes have contributed to a typical "birdlike" face ( Figure 1) . Th e fi ngers were semifl ex, very sclerotic, cold ("Madonna fi ngers"), tapered at the ends, with shortened distal phalanges, and apparent shortening of thinned nail plates (Figure 1) . Th e dorsal sides of hands presented with small calcifi cations over the joints, above which the skin was paper thin and pale yellowish in color. Blotchy hyperpigmentation and telangiectasias were also present. Th e skin of the lower legs and feet exhibited similar characteristics, with pronounced telangiectasias in the form of spots or dark red lacy lines, with cyanosis, hypo-and hyper-pigmentation, and scars, while the nail plates were thickened ( Figure 2) . Th e interdigital areas were pesented with madidation and maceration, erythema, erosions and scaling due to secondary fungal infection. Both sides of the gluteal areas were aff ected by infi ltrates with infl amed skin and fl uctuation. Th ere Figure 1 . Th e face is tightening; the skin is thin, with radial furrows around the mouth, mask-like and expressionless. Th e fi ngers are semifl ex, very sclerotic, with shortened distal phalanges, and apparent shortening of thinned nail plates are deposited in the gluteal soft tissues, presenting as grouped oval pinhead-or millet-sized shadows reaching the size of a "green walnut"; lime salts are also observed in other parts of the pelvis (Figure 4 ). Esophageal peristalsis: the esophagus is normally positioned, dilated, without peristalsis or visible wrinkles, funnel-shaped in the kardia region, with slow fl ow of barium suspension ( Figure 5 ).
Th erapy
Th e patient received systemic therapy: antibiotics (penicillin, gentamicin), corticosteroids, progesterone, vasodilators (pentoxifylline), griseofulvin, and multivitamin preparations; corticosteroids and antimycotics were administered topically. Apart from successful management of the secondary infection, some improvement was achieved by progesterone: the skin was softer, fi nger mobility was slightly better, and the patient subjectively felt better. However, dissolution of calcifi cations was not achieved by the applied therapy.
was a lesion secreting mucus and blood at pressure or spontaneously, and a chalky white material. After surgical intervention, the pseudofi stula was closed, but in the area of the gluteus, indurations in the size of a walnut were palpable. Th e skin of the lower arms, upper arms and the trunk was aff ected to a lesser extent. Calcifi cations were present on the left shoulder with a tendency to secretion (Figure 3 ).
Laboratory and other test results
Laboratory investigations revealed the following abnormal tests: erythrocyte sedimentation rate 78/96, red blood cell count 2,87 x 10 12 /L, hemoglobulin 6,91 g/L, urinalysis revealing recurrent hemoglobulinuria, the urinary fractional 17-ketosteroids in 24 h urine -2,6 mg/24 h (normally 16-18 mg/24 h). Chest and heart X-ray fi ndings: normal Pelvis x-ray (2 views): lime salts (calcium apatite) 
Discussion and Literature Review
Systemic sclerosis (SS) is a rare disease that is more common among women than men, with the peak age of onset between 20 and 50 years (17) . Th e true incidence and prevalence of the disease are unknown, mostly due to a small number of published epidemiological studies, a large variability in the clinical manifestations and severity of the disease, the diffi culty in applying classifi cation criteria, and the variability in the design and methods used in epidemiological studies (18 (19) . According to various studies, the female to male ratio ranges from 1.1: 1 (20) to 14: 1 (21) . Earlier onset of the disease is found in women in regard to men (average age for men 58.9 ± 13.5 years, and 49.2 ± 15.7 years for women (22) . SS is rare in children (23) . Systemic scleroderma (SSc) is a SS aff ecting the skin and a multisystem connective tissue disease of unknown etiology, but it is certainly associated with genetic factors, immune system alterations, and environmental factors (15, 18, 24) . Its pathogenesis involves vascular abnormalities resulting in tissue hypoxia, immune responses manifesting with altered T-and B-lymphocyte functions and production of autoantibodies, through fi broblast dysfunction and excessive collagen synthesis (25, 26, 27) . A wide variety of hypotheses have been off ered to explain the pathogenesis of SSc (25) . . Pelvis x-ray revealing oval pinhead-or millet-sized, grouped shadows in the gluteal soft tissues immune hypothesis and autoimmune events in the pathogenesis of the SSc is supported by: elevated serum interleukin-2 levels, activated lymphocytes in the biopsy specimens, activated monocytes in the peripheral blood, reduced number of CD8+ T lymphocytes, impaired function of NK (natural killer) cells, presence of various autoantibodies and immune complexes (25) .
Some environmental factors may play a role in triggering SSc in persons with genetic predisposition, such as physical trauma (long-term exposure to vibration, burns) (11), viral infections (cytomegalovirus, parvovirus B19, herpes virus) or helicobacter pylori, toxic substances (vinyl chloride, some pesticides, benzene derivatives, silica, trichloroethylene, organic solvents, epoxy resins), and drugs (cocaine, appetite suppressants, penicillamine, Although familial cases of SSc are rare, a family case history is an important factor in the development of the disease (28) . Genetic factors clearly infl uence disease susceptibility as a complex that includes a number of genes and chromosomal loci (24) . Th e HLA (human leukocyte antigen) genes have been implicated in the susceptibility to SSc (29) . Multiple genetic patterns in SSc, and various HLA alleles are associated with diff erent clinical and serological aspects of this disease (30) .
Th e immune hypothesis of SSc patho-genesis emphasizes the role of T cell-derived cytokines implicated in the damage of the blood vessels and indirectly tissue hypoxia; they also directly stimulate fi broblasts to increased collagen synthesis. T helper lymphocytes impair humoral immunity and increase in titer of antinuclear antibodies. Th e diff use, or with other autoimmune diseases) (40) . Our patient was diagnosed with CREST syndrome, fulfi lling all criteria. Due to common absence of some manifestations, some authors believe it is more correct to speak about limited cutaneous scleroderma, and that presence of two of fi ve manifestations is suffi cient (3), however, this is unlikely to be a separate syndrome distinct from systemic sclerosis, but only a subgroup of systemic sclerosis (41) .
Calcinosis is one of the typical manifestations of CREST syndrome, but it may occur in all types of scleroderma. Calcinosis occurs in about 25% of patients with limited SSc and it can be associated with problems of poor peripheral circulation, causing local skin irritation, infl ammation, ulceration and encouraging secondary infection (42) . Calcinosis generally results from dystrophic calcifi cation associated with massive collagen degeneration (43) . Cutaneous deposition of calcium salts in the skin occurs in a variety of clinical settings, beginning as a calcium phosphate nidus and progressing to hydroxyapatite crystal formation within a collagen matrix (43) . Dystrophic calcifi cation is due to accumulation of calcium apatite crystals, with normal levels of serum calcium, phosphorus, and alkaline phosphatase (44) . Calcium deposits develop in the skin, as subcutaneous nodules or massive nodes, mainly in the elbows, knees, fi ngers and toes, but also in other body areas (45) . Sometimes they are visible, sometimes just palpable. Th e overlying skin is thin and often painful. Th e lumps may break through the skin and leak a chalky white liquid. Secondary infections and infl ammations are not uncommon (26) . Our patient presented with multiple calcifi cations of various localization and size, and at one point she needed surgical intervention.
Raynaud's phenomenon (RPh) causes numbness, pain and color changes in fi ngers in a large number of patients with limited SSc (46) . It was fi rst described by Maurice Raynaud in 1862 (47) . It is usually the fi rst and often the only symptom of scleroderma for many years, hence its central role in diagnosis of SSc (45) . It is usually triggered by exposure to cold or emotional stress; due to spasm of small blood vessels (capillaries) one or more fi ngers suddenly turn white, become cold and insensitive (48) . After a few minutes or longer, lack of oxygen in the blood causes cyanosis and pain in the fi ngers, but when the circulation gets normal, hyperemia occurs and the skin gets red (49). Between vitamin K, bleomycin, isoniazid) (11, 31, 32) . Relations between systemic sclerosis and occupational exposure to certain chemicals as triggers of systemic scleroderma have been investigated, for example in construction workers and miners who work with explosives, but later studies showed this association to be unreliable (33) . Th ere are authors who believe that occupational exposure to organic solvents is not signifi cantly associated with systemic scleroderma, and one should be cautious in interpreting the impact of organic solvents and certain chemicals on the development of scleroderma in textile workers (34) . According to the vascular hypothesis of the SS pathogenesis, primary changes aff ect the blood vessels (intimal thickening and vessel lumen occlusion). Endothelial cells are among the fi rst targets, or primary dysfunctional cells in this disease (35) . Precapillar sphincter dilation causes microvascular hypertension, swelling, telangiectasia, and later arteriolar hyperplasia and fi brosis. It is possible that blood vessel insuffi ciency causes tissue injury, whereas fi brosis is a part of the reparation process. Excessive collagen production results in fi brosis of the skin and internal organs; collagen (types I, III, IV, and VII), fi bronectin, glycosaminoglycans, and proteoglycans are deposited in the interstitium and in the intima of small arteries (36) . Collagen deposition may be caused by increase in the number of fi broblasts which produce collagen, or increased collagen production in fi broblasts, but also by reduced collagen degradation.
Th e acronym CREST stands for calcinosis, Raynaud's phenomenon (RPh), esophageal dysmotility, sclerodactyly, telangiectasia syndrome, and dates back to the twentieth century: in 1911, Th ibierge and Weissenbach described a patient with skin calcinosis, RPh, sclerodactyly and telangiectasia, and named it CRST syndrome (37) . In 1964, Winterbauer registered esophageal dysmotility in 4 of his 8 patients with CRST syndrome (38) , and in 1973, Frayha et al. proposed the acronym CREST, due to common occurrence of esophageal dysmotility (39) . Later, various combinations of these clinical manifestations have been described, including REST syndrome (without calcinosis), CRest, "Pure" CREST (in patients with two or more symptoms of CREST, but not enough criteria for limited or diff use systemic sclerosis), "Plus" CREST (association with other forms of systemic scleroderma -limited or the skin becomes fragile and lax, although it looks thicker due to thight connections with the structures underneath (1) . Th e fi ngertips are pointed, fi xed in an acutely fl exed position, with ulcerations and calcifi cations. Th e distal phalanges are shortened or missing, hands are stiff ened into a claw and immovable (48) . Th e nails are dystrophic, dry, striated, deformed. Skin distal to the elbows and knees, but but also of the neck and face may be involved.
Th ree years after the appearance of RPh, our patient presented with skin changes on her fi ngers: fi rst edema, then thickening, thinning, accompanied by reduced mobility and fi xed fl exion. Th ere were also nail changes. Changes on the face and calcifi cations were registered 5 years after the onset of the disease.
Telangiectasias may occur in all types of SSc. Th ey aff ect the face and extremities due to dilation of blood vessels on the skin surface, but also on the mucous membranes (lips, digestive tract) (26) . Th e number and locations of telangiectasias increase over time (50). Our patient had numerous telangiectasias and scars on the shins and dorsum of the feet. Other symptoms of CREST syndrome include fatigue, weakness, breathing diffi culties, dizziness, ulcerations on the fi ngers and toes, poor wound healing, dry mouth and eyes, problems with the teeth.
Although the majority of patients may be classifi ed into diff use or limited SSc, there is a possibility of overlapping clinical symptoms, so all patients are at risk for complications of SSc (51) .
Pulmonary arterial hypertension is a signifi cant cause of mortality in SSc (52) . Th e prevalence of pulmonary arterial hypertension in diff use SSc ranges from 4.9% to 26.7% (53) . However, pulmonary arterial hypertension may be a complication of limited SSc as well (54, 55) .
Scleroderma renal crisis is a rare but serious complication of SSc (56) . It is defi ned as severe hypertension associated with rapid increase in serum creatinine, with or without microangiopathic hemolytic anemia (57) . It occurs in about 20% of patients with diff use SSc, but it also aff ects patients with limited SSc and CREST syndrome (58, 59, 60) . Regular renal function monitoring is recommended for all patients with SSc. Corticosteroids, especially high doses, represent a risk for scleroderma renal crisis (61) .
Primary biliary cirrhosis (PBC) may also be accompanied by CREST syndrome. Th e association episodes the patient is symptom free (26) . Secondary RPh is typical for collagen and vascular diseases; it is usually asymmetric and may be accompanied by ulcerations or necrosis. Primary RPh aff ects younger individuals, after stressful events or exposure to cold; changes are symmetrical without ulcerations and necrosis (3) .
At the age of 43, our patients presented with RPh symptoms, initially after exposure to cold, and later regardless of environmental factors; for two years it was the only manifestation of the disease.
Esophageal dysmotility: Although patients with SSc present with changes in the entire gastrointestinal tract, esophageal involvement is most common (26) . Th e majority of patients with CREST syndrome demonstrate hypomotility. Th e esophageal epithelium may show a cobblestone appearance due to pearly white plaques; apart from subepithelium, fi brosis may also aff ect regions with muscle atrophy (41) . Apart from esophageal aperistalsis, spasms and esophageal stricture have rarely been reported. Esophageal manometry and radionuclide transit test are better than radiography in the detection of motor abnormalities (41) .
Esophageal dysmotility is usually found in the lower two-thirds of the esophagus and the lower esophageal sphincter, due to smooth muscle atrophy and fi brosis of the lamina propria and submucosa, atrophy and mucosal erosion and disruption of the capillary network (1). Patients often state they must drink liquids to swallow solid food (50). Esophageal refl ux is common (16) , as well as nausea, vomiting, weight loss, diarrhea, constipation and bleeding (45, 49) . It has been pointed that symptoms of esophageal refl ux are twice as common as dysphagia (41) .
After fi ve years since the beginning of the disease, our patient presented with diffi culties in swallowing, heartburn, and regurgitation with large meals.
Sclerodactyly is the most easily recognizable manifestation, but it is not prominent in all patients (50). It is thickening which generally only involves the skin of the fi ngers (and toes) distal to the metacarpophalangeal joints in CREST syndrome. Sclerodactyly evolves through three phases: the edematous phase, indurative phase, and atrophic phase (26) : the edematous phase begins with fi nger swelling, morning stiff ness, and arthralgias; in the second phase the skin becomes thickened, shiny, without wrinkles, erythematous, and itchy; in the last, atrophic phase, Th ese characteristics also include: RPh episodes with fast skin changes, changes on the trunk and acral parts of the body, presence of tendon friction rubs, early and signifi cant appearance of interstitial lung disease, chronic renal failure with oliguria, diff use gastrointestinal diseases, with involvement of myocardium, genitourinary and musculoskeletal system, absence of ACA, dilatation of capillaries and nailfold capillary destruction, autoantibodies against Topoisomerase I (Scl 70) (in 30% of patients) (10, 16) . Th e limited cutaneous SSc is characterized by slow progression, and less frequent and later spread on the internal organs. RPh is recorded in the course of several years, skin sclerosis aff ects the hands, face, legs and forearms (acral parts); there is a signifi cantly lower incidence of pulmonary hypertension, with or without interstitial lung disease, trigeminal neuralgia, calcifi cation and skin telangiectasia, often with ACA (anticentromere antibody that reacts with the kinetocore of metaphase chromosomes) in 40 -70% (41), dilated nailfold capillaries (10) . Systemic sclerosis sine scleroderma (ssSSc) is a rare disorder in which patients develop vascular and fi brotic damage to internal organs, in the absence of cutaneous sclerosis (72) . Brazilian authors studied 947 consecutive patients with SSc and 8.3% were classifi ed as ssSSc (73) . In this series, patients with ssSSc had a relatively mild type of disease with good prognosis. Th e disease was characterized by (13): RPh with a peripheral vascular equivalent (digital pitting scars, digital tip ulcers, digital tip gangrene and abnormal nailfold capillaries), positive antinuclear antibodies (ANA), one visceral organ involvement typical of SSc (any one of the following: distal esophageal hypomotility, small bowel hypomotility, pulmonary interstitial fi brosis, pulmonary hypertension, cardiac involvement typical of scleroderma or renal failure consistent with scleroderma renal crisis) and absence of another defi ned connective tissue or other disease as a cause of signs and symptoms cited above. Scleroderma overlap syndromes mostly include simultaneous occurrence of sclerosis and some autoimmune systemic diseases (polymyositis, systemic lupus erythematosus or rheumatoid arthritis). If only RPh, ulcers, digital pitting ulcers, and ANA are present, with no other signs of systemic disease, it is presystemic scleroderma (1), corresponding with prodromal cutaneous sclerosis syndrome. of these two diseases is explained by a common autoimmune mechanism, and it is considered a distinct entity (PBC-CREST). Along with keratoconjunctivitis sicca, it is known as Raynaud's syndrome. According to Tojo and associates (62) , patients with PBC-CREST have milder symptoms than patients with PBC or CREST alone, but have a larger number of esophageal varices. High titers of anti-centromere antibodies (ACA), low titers of antimitochondrial antibodies, high prevalence of HLA-DR9 and better prognosis are registered in patients with PBC-CREST. Th is association is well known in women, but it may also occur in men (63) .
Using non-invasive cardiovascular magnetic resonance (CMR) imaging (64), coronary artery abnormalities and myocardial fi brosis can be registered, and all patents with SSc present with multiple fi brotic areas (65) . Th e pathogenesis of the fi brotic lesions in SSc is still unclear. However, a spasm of small coronary arteries (myocardial Raynaud's phenomenon) has been suggested as a possible mechanism (65). Mavrogeni et al. (66) , used CMR to evaluate 5 patients with CREST syndrome and 5 patients with SSc. All patients with CREST syndrome presented with coronary artery ectasia, whereas patients with SSc were without cardiac symptoms with normal coronary artery fi ndings, but patchy fi brosis was identifi ed in all of them (66).. Anemia has also been associated with CREST syndrome (67) as a result of jejunal telangiectasias, with normal colposcopic fi ndings and esophagitis.
Lauritano et al. (68) observed tongue rigidity and some speckled red alternating with white spots on the hard palate and in the vestibule in patients with Sjögren's syndrome and CREST.
CREST syndrome is rarely associated with other malignancies (69) . It has been suggested that patients with scleroderma and Barrett's metaplasia are at increased risk of complications, such as strictures or adenocarcinoma, cases of CREST syndrome and lung adenocarcinoma, esophageal carcinoma, and adenocarcinoma of the third portion of the duodenum (41, 69) .
Hachulla and Launay (70) reviewed the literature concerning the diagnosis and classifi cation of SSc, describing characteristics of certain forms of the disease. In diff use cutaneous form of SSc, disease progression is very fast, with a high incidence of renal, cardiac and pulmonary alterations (71) . tests: antinuclear antibodies (ANA) (90% -95% in limited cutaneous and diff use cutaneous SSc) (75) . Other tests are used depending on the aff ected organ: pulmonary function tests, chest radiography, electrocardiogram, gastrointestinal motility testing, renal function tests, etc.
C. Diagnostic criteria of the American College of Rheumatology (ACR) (9) . Th e patient should fulfi ll a major criterion or two of the three minor criteria:
I Major criteria -Scleroderma proximal to the digits, aff ecting limbs, face, neck or trunk -this is a single major criterion. T. -telangiectasias. Th e classifi cation of defi nite SSc requires at least three of the above criteria. Although presence of topoisomerase 1 (Scl-70) is extremely rare in localized scleroderma, autoantibodies to topoisomerase 11 were found in 70% of patients with localized scleroderma, and 85% of patients with generalized morphea (41) .
Classifi cation criteria for systemic sclerosis, published by the American College of Rheumatology/ European League Against Rheumatism Collaborative Initiative (77) in 2013, include 8 criteria validated by a number of points, so that the defi nite diagnosis of SSc is set if the total score is 9 or more. Th ese are: 1) skin thickening of fi ngers of both hands extending proximally to the metacarpophalangeal joints (suffi cient criterion -9 points); 2) fi nger tip lesions, edema -2 points, sclerodactyly -4 points; 3) fi nger lesions, ulcerations -2 points; fi nger tippitting scars -3 points; 4) telangiectasias -2 points; 5) abnormal nailfold capillaries -2 points; 6) lung involvement, pulmonary arterial hypertension -2 points; interstitial lung disease -2 points; 7) RPh -3 points; 8) scleroderma related antibodies -3 points.
Rare cases of nodular and keloidal scleroderma have also been described. Th ere are two categories: 1) systemic scleroderma accompanied by generalized distribution of ivory-colored subcutaneous nodules 3-20 mm in diameter, whose histology shows fi bromatous changes or fi brinoid necrosis, and 2) localized scleroderma, subcutaneous morphea/ deep morphea/morphea profundus, with localized or generalized nodules; the skin is pigmented or hypopigmented, while most morphea nodules are said to be non-progressive (41) . Localized scleroderma is characterized by extensive deposition of collagen with a thickening of the dermis and/or subcutaneous tissue. Unlike systemic sclerosis, it presents without sclerodactyly, RPh, nail changes, telangiectasia and progressive involvement of internal organs (41) .
Speaking of patients with SSc, the most common subsets are limited cutaneous (approximately 60% of patients with systemic sclerosis) and diff use cutaneous (approximately 35% of patients with systemic sclerosis), whereas systemic sclerosis without scleroderma aff ects about 5% (16) . Approximately 15% of patients have pulmonary hypertension, and 10% have overlap syndromes. Th e diagnosis of systemic sclerosis is based on the following (11, 41):
A. Clinical fi ndings: 1) Medical history (on the overall health status, development of the disease and symptoms, exposure to possible precipitating factors, symptoms involving the lungs, heart, gastrointestinal tract, kidneys, muscles, etc.). 2) Clinical examination of the skin and other organs, and diagnostic criteria; B. Diagnostic tests: Erythrocyte sedimentation rate, blood count, biochemical analyses; Skin biopsy; X-ray of the lungs, heart and esophagus; CT scan o the bones (in patients with calcinosis CT should be done when radiography fi ndings are normal); Esophageal manometry and radionuclide transit are better than radiography for showing motor abnormalities; plethysmography, laser Doppler fl owmetry, thermography, fi nger systolic blood pressure are used in the RPh (26); Cardiovascular magnetic resonance imaging is used to detect changes in the coronary arteries and the heart muscle, but major diff erences between limited and diff use SSc are not probable (74) .
Th e diagnosis of RPh is made using: plethysmography, laser Doppler fl owmetry, thermography, fi nger systolic blood pressure (26) (91) . Anti-fi brillin-1 antibodies (U1-RNP) indicate a serious involvement of skin and systemic organs with high mortality, whereas antinucleolar antibodies indicate a limited form of the disease; however, they can be detected in patients with pulmonary hypertension and pulmonary fi brosis (75) . Anti-RNA Polymerase III (Pol 3) antibodies are registered in 10 -20% of patients with SSc, pointing to a serious disease with scleroderma, renal crisis and association with malignancy (91) .
Th ere is a registered association between SSc and various HLA alleles (92) . Scleroderma is associated with HLA-DQA1* 0501 and DQB1* 0301 allele in all ethnic groups, DRB1* 1104 in Caucasians and Hispanics, and DRB1* 0804 in African Americans (93) . HLA-DRB1 alleles are associated with limited scleroderma (29) , and B* 62, DRB1* 11 and DRB1* 07 with diff use scleroderma (1, 94) . Pulmonary fi brosis is associated with HLAB* 62 and HLA Cw* 0602, and pulmonary hypertension with HLAB* 13 and HLAB* 65 (29) . Th ere is a correlation between the connective-tissue growth factor (CTGF), and systemic sclerosis, particularly in patients with anti-Scl-70 antibodies and pulmonary fi brosis (95) . Th e presence of certain HLA alleles correlates with the presence of autoantibodies specifi c for systemic scleroderma (93, 96) . Diff erential diagnosis includes (16, 41) : RPh of occupational origin, vibration-induced injuries, other connective tissue diseases or mixed connective tissue diseases (eg, rheumatoid arthritis or systemic lupus erythematosus), undiff erentiated connective tissue disease, amyloidosis, paraneoplastic syndrome, and pseudoscleroderma (congenital, metabolic, toxic, chronic graft-versus-host disease).
Despite numerous new fi ndings, there is still no therapeutic algorithm that can signifi cantly change the natural course of the disease. Symptomatic treatment is of great importance (35) . Th e therapy of SSc depends on the segment in the pathogenesis of the disease which is being treated, e.g. changes in the vascular system, increased collagen synthesis, or modifi ed immune reactivity (1) . Vasoactive treatment includes: prostacyclin, low molecular weight dextran, stanozolol, nifedipine, captopril, ketanserin and plasmapheresis. Collagen production is aff ected by: D-penicillamine, pentoxifylline, coagulation factor XIII, cyclofenil, In recent years a number of authors (78 -82) is working on the revision of the classifi cation criteria, including a broad range of clinical and laboratory elements that characterize SSc, which should contribute more accurate diagnosis, therapy and prevention of complications of the disease. Nailfold capillary microscopy (NCM) is a method used to assess the degree of capillary dilation (83) , being very important for early diagnosis of SSc. NCM has signifi cantly improved the identifi cation of clinical diff erences (84) , and that is why diagnostic sensitivity of ACR criteria may be markedly improved by addition of simple clinical variables, including NCM abnormalities and ACA positivity, as novel minor criteria (83) . Capillary patterns may correlate with visceral involvement and capillaroscopy thus has the potential as a screening tool to enable early diagnosis of organ involvement in systemic sclerosis, as well as early therapy and prevention of disease progression (85) . Th is method allows: early diagnosis of systemic sclerosis without skin involvement, diff erentiation of primary RPh from secondary RPh and follow up of disease progression (86) . Today, videocapillaroscopy is most widely used (87) . When comparing NCM and dermoscopy, most nailfold capillary images can be classifi ed and assessed with higher accuracy (88) .
Serological tests are of great importance in the diagnosis and diff erential diagnosis, especially related to the presence of antinuclear antibodies (ANA), which are the expression of autoimmune response (35) , and clinically are associated with pulmonary and arterial hypertension, and interstitial lung disease; ANA may be present in healthy individuals as well, but in low percentage (89) . Anticentromere antibodies (ACA) are found in 40 to 70% of patients with limited cutaneous sclerosis and are associated with calcinosis, RPh, esophageal dysmotility, sclerodactyly, telangiectasia, and pulmonary arterial hypertension; they are found only in 2 to 5% of patients with diff use scleroderma, when they are associated with digital ulceration or digital loss. ACA fi ndings indicate capillary involvement (90) . Anti-topoisomerase I (anti-Scl-70) autoantibodies are found in 20 to 40% of patients with diff use cutaneous sclerosis, and only 6% with limited cutaneous SSc; they are associated with rapid progression of skin thickening, scleroderma, renal crisis, pulmonary fi brosis, joint, muscle and heart involvement, hypertension and In some cases, clinical improvement in patients with SSc is obtained by UVA-1 phototherapy (98) .
Meta-analysis was conducted to determine the effi cacy of calcium channel blockers for RPh, pointing to a moderate reduction in the frequency and severity of ischemic attacks (99) . Th e following blockers were evaluated: nifedipine, nicardipine, nisoldipine, diltiazem; nifedipine was indicated for RPh, since it signifi cantly reduced the frequency and severity of ischemic attacks with highest therapeutic effi cacy (100). Type V phosphodiesterase inhibitor, sildenafi l, stimulates accumulation of cyclic guanosine monophosphate, decreasing intracellular calcium concentrations, inducing relaxation of the vascular smooth muscle and consequent dilation (101, 102) . Several-week use of sildenafi l causes signifi cant reduction in the frequency and severity of RPh (102) . A synthetic phosphodiesterase III inhibitor, cilostazol increases conduit vessel diameter in patients with primary and secondary RPh, with a favorable impact on conduit vessel responsiveness to cold in patients with primary RPh without aff ecting microvascular fl ow or symptoms (103) . Selective alpha-adrenergic receptor blocker acts in the recovery from coldinduced vasospasm in scleroderma patients (104) . If topical glyceryl trinitrate is used in the treatment of primary RPh or limited SSc, it may cause endotheliumdependent vasodilator eff ect (105) .
Th e mechanism of calcinosis formation is not entirely understood, and no eff ective treatment is available (106) . However, low doses of warfarin may be eff ective in some patients with early and moderate SSc. Minocycline may be eff ective in the control of calcinosis in systemic sclerosis. Th e mechanism of action may be mainly through inhibition of matrix metalloproteinases and anti-infl ammatory eff ects (42) . Physical therapy of calcinosis includes: extracorporeal shock wave lithotripsy (107), carbon dioxide laser (108) , and erbium laser (109) . Treatment of fi nger calcinosis has a wide range of possibilities depending on the extent of calcifi cations and the involvement of deep structures. From a surgical point of view, simple removal is adequate in minor outpatient cases, whereas radical debridement is required in the major and more painful cases (44) . Laser surgery may reduce telangiectasias, and amputation is sometimes necessary in gangrene.
Topical therapy includes (11):
colchicine, griseofulvin, 13-cis retinoic acid. Immune therapy includes: prednisone, cyclophosphamide, azathioprine, cyclosporine. Hinchcliff and Varga (16) presented a treatment overview of organ specifi c complications of SSc (16): Raynaud's phenomenon --Adrenergic blockers, angiotensin-II receptor blockers, long-acting calcium channel blockers (dihydropyridines), pentoxifylline (Trental), stellate ganglionic blockades, digital sympathectomy; skin fi brosis -immunomodulatory drugs (d-penicillamine, mycophenolate mofetil, cyclophosphamide; gastroesophageal refl ux -antacids, histamine H2 blockers, proton pump inhibitors;
intestinal dysmotility or bacterial overgrowth -antibiotics, correction of nutritional defi ciencies, promotility agents; pulmonary fi brosis or alveolitis -immunomodulatory drugs, initial therapy with oral or intravenous cyclophosphamide, maintenance therapy with azathioprine; pulmonary arterial hypertension -diuretics, endothelin-1 receptor inhibitors (bosentan), oxygen, phosphodiesterase-5 inhibitors (sildenafi l), prostacyclin analogues (epoprostenol, treprostinil, iloprost), warfarin (sometimes used in patients with recurrent pulmonary thromboembolic disease); scleroderma renal crisis -dialysis, short-acting angiotensin-converting enzyme inhibitors.
Manno and Boin (97) gave an overview of immunomodulators which are used in the therapy of SSc including: category, name of the drug, mechanism of action, and recommended doses:
1. nonselective immunosuppressive therapy: cyclophosphamide, mycophenolate mofetil, azathioprine, methotrexate;
2. T-cell-targeted immunotherapy: cyclosporine A, antithymocyte globulin, extracorporeal photoimmunotherapy or photopheresis, sirolimus (rapamycin);
3. B-cell-targeted immunotherapy: rituximab; 4. intravenous immunoglobulins; 5. biological immunotherapy: anti-TNF- agents, infl iximab;
6. antifi brotic therapy: CAT-192, imatinib mesylate; 7. cell-based immunotherapy: autologous hematopoietic stem cell transplantation.
broad-spectrum topical antibiotics; nitroglycerin ointment for ischemic ulcers; topical antipruritics; emollients. Other forms of therapy (31, 32) :
patient education on the characteristics of the disease and awareness of urgent problems; physiotherapy to promote joint mobility and muscle strength;
exercises to maintain range of motion (mouth, face and hand stretches); avoid tobacco and maintain healthy weight; nutritional advice, and supplements if needed; for Raynaud's phenomenon: avoid cold and trauma, use warm clothing or heated clothing; For an attack -warm the body, hands and feet, use gentle arm movements or gentle massage to help restore circulation;
occupational therapists -for adaptations to assist in daily living; camoufl age products -cosmetics. Skin protection: Avoid harsh soaps and detergents; reduce bathing frequency (bathe just once a day or every other day, using warm rather than hot water); apply sunscreen and increase moisture levels in your home by using a humidifi er; practice good oral hygiene. Th e prognosis and course of the disease indicate that although spontaneous remission is possible, SSc is essentially a chronic disease with progressive course with possible crises due to organ involvement. Th e patient should be informed about the objective circumstances in terms of clinical manifestations and treatment options, with high commitment of the entire team of doctors and psychotherapy.
Conclusion
When classifying systemic scleroderma into two groups -diff use and limited, with CREST syndrome as a variant of the latter, it should be considered that both types represent clinical variants of systemic sclerosis, share similar visceral involvement, laboratory abnormalities and the course which is not invariable, as shown in our patient. We reported a case of a patient with typical features of limited SSc, and all the symptoms of CREST syndrome, in whom the disease lasted for 23 years; therapeutic modalities provided only temporary improvement, eventually resulting in a fatal outcome.
